Myotonia is a muscle phenomenon in which the fibers keep contracting when they should be relaxing, producing a stiffness that the person cannot voluntarily release on command. If you grip a doorknob and then try to let go, your fingers stay curled for several seconds before slowly loosening. The underlying problem sits at the level of the muscle cell membrane, where ion channels that normally shut off electrical activity after a contraction instead keep firing or fail to dampen excitability quickly enough. Myotonia appears across a surprisingly wide range of genetic conditions, from relatively benign forms that cause nothing more than annoying stiffness to severe multisystem diseases that shorten lifespan.
What Myotonia Feels Like Day to Day
People with myotonia describe muscle stiffness rather than weakness, at least early on. The hands are often the first place it becomes obvious: opening a fist after gripping something takes noticeable effort, and the stiffness can be visible to anyone watching. Legs stiffen after sitting still, making the first few steps out of a chair look awkward or halting. Eyelids and jaw muscles are frequently involved as well, so blinking can feel sluggish and chewing tough food becomes a chore. The severity swings widely from one person to the next, and even from hour to hour in the same person.
One of the more counterintuitive features is the “warm-up phenomenon.” In many forms of myotonia, repeated muscle use actually loosens the stiffness rather than making it worse. Someone whose hand locks up when they first grip a pen finds that after opening and closing the fist a few times, the stiffness fades and the muscle behaves more normally. This warm-up effect is well documented in chloride channel myotonias and has also been observed in certain sodium channel mutations.
Cold makes things worse for nearly all myotonic conditions, but in one specific subtype, paramyotonia congenita, the relationship with cold is dramatic. Cooling the muscles doesn’t just increase stiffness; it can trigger outright weakness. In clinical studies, clear loss of strength appeared when muscle temperature dropped to around 31–32°C, and the weakness worsened the more the person tried to use the muscle in the cold.1PubMed. Influence of temperature on isometric contraction and passive muscular tension in paramyotonia congenita (Eulenburg) Paramyotonia congenita also reverses the warm-up rule: here, repeated contraction makes the stiffness worse, not better, which is why it’s sometimes called “paradoxical myotonia.”2PubMed. Clinical study of paramyotonia congenita with and without myotonia in a warm environment Families with paramyotonia congenita had no myotonia in a warm environment, but in the cold they developed this paradoxical worsening with activity. Understanding whether someone’s stiffness improves or worsens with repeated use is one of the first clinical clues pointing toward which type of myotonia they have.
When the Ion Channel Itself Is Broken
The non-dystrophic myotonias are conditions where the muscle stiffness is caused directly by a faulty ion channel in the muscle cell membrane, and the muscle stiffness is essentially the whole disease. The rest of the body works fine. These fall into two groups based on which channel is affected: chloride channels and sodium channels.
Chloride channel myotonias, known as myotonia congenita, come in two forms. Thomsen’s disease is inherited in a dominant pattern, meaning one copy of the faulty gene is enough to cause symptoms, while Becker’s disease follows a recessive pattern and tends to be more severe. Both are caused by mutations in the CLCN1 gene, which encodes a voltage-gated chloride channel in skeletal muscle.3PubMed. Mutations in the human skeletal muscle chloride channel gene (CLCN1) associated with dominant and recessive myotonia congenita Chloride channels normally help stabilize the muscle membrane after a contraction fires. When those channels don’t work properly, the membrane stays excitable longer than it should, and the muscle keeps contracting when it should be relaxing.4PubMed Central. Muscle channelopathies: the nondystrophic myotonias and periodic paralyses People with myotonia congenita often develop visibly well-muscled physiques, sometimes called a “Herculean” build, because their muscles are essentially always getting a low-grade workout from the ongoing contractions.
Sodium channel myotonias work through a different mechanism. Instead of the membrane losing its braking system (as with chloride), the accelerator gets stuck. Mutations in the SCN4A gene, which encodes the Nav1.4 sodium channel, cause the channel to stay open too long or reopen too easily, flooding the muscle fiber with sodium and keeping it electrically active. In paramyotonia congenita, specific mutations slow down the process of inactivation, the step where the channel shuts itself off after firing, and speed up recovery, so the channel is ready to fire again sooner than normal.5PubMed Central. Paramyotonia congenita mutations reveal different roles for segments S3 and S4 of domain D4 in hSkM1 sodium channel gating One well-studied mutation, N1366S, showed that cold temperatures shift the channel’s behavior even further out of balance, explaining why cold triggers such dramatic symptoms in paramyotonia congenita.6PubMed Central. N1366S mutation of human skeletal muscle sodium channel causes paramyotonia congenita Other mutations in the same channel cause potassium-aggravated myotonia, where stiffness worsens after eating potassium-rich foods.
Myotonic Dystrophy and the Problem That Goes Beyond Muscle
Myotonic dystrophy is fundamentally different from the non-dystrophic forms. Here, myotonia is just one symptom in a disease that affects the heart, brain, eyes, endocrine system, and more. The mechanism is also completely different: instead of a broken ion channel, the problem is toxic RNA that gums up the cell’s ability to process its own genetic instructions.
Myotonic dystrophy type 1 (DM1) is caused by a repeating stretch of DNA, specifically CTG triplets, in the DMPK gene. Healthy people have a small number of these repeats, but in DM1 the sequence expands to hundreds or even thousands of copies. When this expanded DNA is copied into RNA, the resulting long CUG-repeat RNA doesn’t leave the nucleus to be translated into protein the way it should. Instead, it clumps into visible clusters called nuclear foci and acts as a trap for regulatory proteins that the cell needs to process other RNAs correctly.7Human Molecular Genetics. Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons One key protein, MBNL1, gets sequestered on the toxic RNA, while another, CUGBP1, gets abnormally activated. The downstream effect is widespread disruption of alternative splicing, meaning the cell starts producing the wrong versions of numerous proteins, including the chloride channel that prevents myotonia in healthy muscle.8PubMed Central. Pathogenic mechanisms of myotonic dystrophy
This splicing disruption explains why DM1 hits so many organ systems. Cardiac conduction defects, cataracts, insulin resistance, excessive daytime sleepiness, and cognitive changes all stem from the same underlying RNA toxicity disrupting protein production in different tissues.9PubMed Central. Cardiac Involvement in Myotonic Dystrophy Type 1: Mechanisms, Clinical Perspectives, and Emerging Therapeutic Strategies Cardiac involvement is a leading cause of death in DM1, with arrhythmias and conduction block developing even in patients whose muscle symptoms seem mild.
Myotonic dystrophy type 2 (DM2) follows a parallel mechanism but with a different gene and repeat unit. Here, a CCTG tetranucleotide expansion in the CNBP gene produces toxic CCUG-repeat RNA that similarly disrupts splicing.10PubMed Central. Updated Structure of CNBP Repeat Expansions in Patients With Myotonic Dystrophy Type 2 and Its Implication for Standard Diagnostics DM2 tends to be milder overall, with proximal muscle pain and stiffness as dominant complaints rather than the distal weakness and wasting seen in DM1. Myotonia in DM2 is often less prominent clinically, and the cardiac and cognitive involvement, while real, is generally less severe. Recent research has also identified mitochondrial dysfunction as an additional layer of cellular damage in DM2, which may contribute to the muscle pain and fatigue that patients report as particularly bothersome.11PubMed Central. Multi-level profiling unravels mitochondrial dysfunction in myotonic dystrophy type 2
Congenital Myotonic Dystrophy
The most severe end of the DM1 spectrum is congenital myotonic dystrophy (CDM1), which presents at birth. Affected newborns show profound hypotonia (floppiness, which is in a sense the opposite of myotonia), difficulty breathing, and feeding problems. CDM1 is almost exclusively inherited from the mother, because the CTG repeat tends to expand dramatically during maternal transmission.12American Journal of Human Genetics. DMPK Methylation Dictates Disease Severity, Maternal Bias, and Age of Onset in Congenital Myotonic Dystrophy Research has shown that methylation of the DMPK gene region plays a role in determining disease severity and the maternal bias of inheritance. Children who survive the neonatal period face intellectual disability, progressive muscle disease, and the same multisystem complications as adult-onset DM1, but starting far earlier in life. CDM1 is distinct enough from classic adult-onset DM1 that it is sometimes misdiagnosed as a different neuromuscular condition entirely before genetic testing clarifies the picture.
How Myotonia Is Treated
For the stiffness itself, the first-line medication in most forms of myotonia is mexiletine, a sodium channel blocker originally developed as an anti-arrhythmic drug. Mexiletine works by stabilizing the muscle membrane and reducing the abnormal electrical discharges that cause prolonged contraction. In myotonic dystrophy type 1, a clinical trial found that both 150 mg and 200 mg doses significantly reduced grip relaxation time, the standard measure of how long it takes the hand to open after a firm squeeze, without serious side effects or concerning changes on electrocardiogram.13PubMed Central. Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1 In non-dystrophic myotonias, a multicenter randomized trial confirmed mexiletine’s effectiveness for reducing muscle stiffness across chloride and sodium channel subtypes alike.14JAMA. Effect of Mexiletine on Muscle Stiffness in Patients With Nondystrophic Myotonia Evaluated Using Aggregated N-of-1 Trials
Mexiletine does not cure myotonia or slow the progression of myotonic dystrophy; it simply dials down the stiffness. Other medications used when mexiletine isn’t tolerated include certain anticonvulsants and other membrane-stabilizing drugs, though the evidence base for these alternatives is thinner. For myotonic dystrophy specifically, managing the muscle stiffness is only one piece of a much larger clinical puzzle that includes cardiac monitoring, screening for cataracts and diabetes, and managing fatigue and cognitive symptoms.
Lifestyle adjustments matter too. Many people with non-dystrophic myotonia learn to “warm up” before activities that require fine motor control or quick movements. A person with myotonia congenita might clench and unclench their fists several times before trying to write or grip a tool. Avoiding sudden cold exposure helps in paramyotonia congenita, and some patients with potassium-aggravated forms learn to modify their diet.
Why Anesthesia Is a Serious Concern
One of the most important practical considerations for anyone with myotonia is the risk posed by certain anesthetic agents during surgery. Succinylcholine, a depolarizing muscle relaxant commonly used during intubation, can trigger a life-threatening acute myotonic reaction in which the muscles go into sustained, uncontrollable contraction. The jaw can clamp shut so forcefully that the airway cannot be secured, and the resulting whole-body rigidity can make ventilation impossible.15PubMed. Acute myotonic reaction during succinylcholine anaesthesia Because succinylcholine works by depolarizing the muscle membrane, and myotonic muscle is already hyper-excitable, the combination is extremely dangerous.
Clinical guidance is unambiguous: depolarizing muscle relaxants should be avoided at all times in patients with any form of myotonia.16PubMed Central. Anaesthesia and neuromuscular disorders: what a neurologist needs to know Non-depolarizing alternatives are safe substitutes. The challenge is that myotonia is rare enough that not every anesthesiologist will have encountered it before, and if the patient doesn’t disclose the diagnosis or it hasn’t yet been made, the reaction can come as a complete surprise. People with myotonia are generally advised to carry medical alert identification and to make sure any surgical team is explicitly informed well before the day of a procedure. This applies equally to non-dystrophic myotonias, which are easily overlooked because the patient may otherwise seem perfectly healthy.
Research Aimed at the Root Cause
Current treatments for myotonia address symptoms rather than the underlying genetic defect. For the non-dystrophic myotonias, symptom control with mexiletine or similar drugs is often enough to maintain a good quality of life, so the research urgency centers more on myotonic dystrophy, where the disease is progressive and multisystem.
The most promising experimental approach for DM1 targets the toxic RNA itself. Antisense oligonucleotides (ASOs) are short synthetic stretches of genetic material designed to bind to the expanded CUG-repeat RNA and either mark it for destruction or prevent it from trapping MBNL1 and other regulatory proteins. In a mouse model of DM1, systemic treatment with one such ASO (ISIS 486178), aimed at the 3′ untranslated region of the DMPK gene, reduced toxic RNA levels by about 70% in skeletal muscle and 30% in the heart. Treated mice showed improved body weight, muscle strength, and muscle tissue structure with no obvious toxic side effects.17Molecular Therapy Nucleic Acids. Targeted Reduction of Mutant DMPK mRNA by Antisense Oligonucleotide Improves Myotonic Dystrophy Type 1 Clinical and Molecular Phenotypes The significance of this result is that it demonstrated muscle weakness in DM1 is at least partly reversible if the toxic RNA is cleared, rather than being caused by irreversible muscle damage. Several pharmaceutical programs are now working on getting ASOs into human trials for DM1, though delivering enough drug to all affected tissues, especially the heart and brain, remains a major technical challenge.
Other avenues of research include small molecules that disrupt the interaction between CUG-repeat RNA and MBNL1, gene-editing approaches using CRISPR to shorten or eliminate the repeat expansion, and efforts to correct specific downstream splicing defects one at a time. None of these approaches have yet reached late-stage clinical trials, but the pace of molecular-level research in myotonic dystrophy has accelerated considerably since the RNA toxicity mechanism was established.
Myotonic Goats and What They Taught Us
Before the genetics of myotonia were understood at the molecular level, much of what researchers knew about the role of chloride channels in muscle excitability came from studying a breed of goats colloquially known as “fainting goats.” These animals carry a naturally occurring mutation in the goat chloride channel gene (gClC-1): a single amino acid substitution, alanine to proline, in the channel’s carboxyl terminus. When this mutation was tested in the laboratory, it shifted the channel’s activation so dramatically (by about 47 millivolts) that the channel barely opened at normal resting membrane voltages, effectively wiping out chloride conductance in the muscle.18PubMed. Molecular basis for decreased muscle chloride conductance in the myotonic goat The result: when startled, the goats’ muscles contract and don’t relax, causing them to stiffen and topple over. They don’t actually faint or lose consciousness; the muscles simply lock up.
The myotonic goat was critical for establishing that reduced chloride conductance alone was sufficient to produce myotonia, a finding that directly informed understanding of human myotonia congenita. These goats remain a useful natural model because their mutation is remarkably similar in its functional effect to human CLCN1 mutations, even though the specific genetic change differs. The breed is now more of a novelty livestock animal than a research tool, but its contribution to the science of membrane physiology was genuinely significant. It’s a reminder that rare genetic quirks in animals and humans often reflect the same underlying biology, and that studying one can illuminate the other in ways that laboratory models alone sometimes cannot.
Distinguishing Myotonia from Conditions That Mimic It
Not everything that looks like myotonia is myotonia. Several other conditions produce muscle stiffness or delayed relaxation that can be confused with true myotonia, and getting the distinction right matters because the treatments and prognoses differ sharply.
Neuromyotonia (also called Isaacs syndrome) produces continuous muscle fiber activity that causes stiffness, cramps, and visible rippling under the skin. It originates at the nerve terminal rather than the muscle membrane, and is often autoimmune in nature, caused by antibodies against potassium channels at the neuromuscular junction. Electrical testing of the muscle shows distinctive neuromyotonic discharges that differ from the waxing-and-waning pattern of true myotonia.19PubMed Central. Segmental neuromyotonia Stiff-person syndrome, hypothyroid myopathy, and Brody disease are other conditions that produce muscle stiffness through entirely different mechanisms. On an electromyogram (EMG), true myotonia produces a characteristic sound that electrophysiologists describe as resembling a dive-bomber, a repetitive discharge that waxes and wanes in both frequency and amplitude. This EMG signature is often what clinches the diagnosis and separates myotonia from its various mimics.
Genetic testing has made definitive diagnosis faster, but an EMG remains valuable as an initial screening tool because it can identify myotonic discharges even when the clinical stiffness is subtle. In paramyotonia congenita, cooling the hand during EMG recording causes the electrical pattern to shift from repetitive discharges to myotonic potentials, and then to diminished recruitment as weakness sets in, a progression that tracks closely with what the patient experiences in real life.20Muscle & Nerve. Temperature-sensitive repetitive discharges in paramyotonia congenita This kind of provocation testing, deliberately cooling the muscle during the exam, can be the key to diagnosing forms that are not obvious at room temperature.